VAM
NVAX icon

Visium Asset Management’s Novavax NVAX Stock Holding History

Visium Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-830
Closed -$185K – 1099
2015
Q2 		$185K Buy
+830
New +$146K ﹤0.01% 996

Other funds holding NVAX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Visium Asset Management's NVAX Position: Q3 2015 in Review

Visium Asset Management sold out of Novavax (NVAX) in Q3 2015, closing a stake of 830 shares — an estimated $185K sold.

Visium Asset Management first reported a position in NVAX in Q2 2015 and held it in 1 quarter. The position peaked at $185K in Q2 2015. 190 funds tracked by Wall St. Rank hold NVAX as of Q3 2015.

  • Visium Asset Management reported no remaining Novavax position as of Q3 2015 after selling out during the quarter.
  • Visium Asset Management sold 830 Novavax shares in Q3 2015, an estimated $185K.
  • Visium Asset Management first reported a position in Novavax in Q2 2015 and held it in 1 quarter.
  • Visium Asset Management's Novavax position peaked at $185K in Q2 2015.
  • 190 funds tracked by Wall St. Rank held Novavax as of Q3 2015.

Based on Visium Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.